What is Eosinophilic Asthma?
Eosinophilic asthma is a distinct phenotype of severe asthma characterized by persistent elevation of eosinophils in the blood and airways, driven by type 2 (T2) inflammation, typically presenting as adult-onset disease with frequent exacerbations and progressive airway obstruction. 1
Core Pathophysiology
Eosinophilic asthma represents a specific inflammatory pattern within the broader spectrum of asthma. While the foundational definition of asthma describes it as a chronic inflammatory disorder involving multiple cell types including mast cells, eosinophils, neutrophils, T lymphocytes, and epithelial cells 2, eosinophilic asthma is distinguished by the dominant and persistent role of eosinophils as primary disease drivers rather than bystanders 1.
The pathophysiology centers on:
- Interleukin-5 (IL-5) mediated signaling that regulates eosinophil maturation, survival, migration, and activation 3, 4
- Release of cytotoxic granule proteins, cytokines, and extracellular traps from eosinophils causing direct tissue damage 3
- Contribution to airway epithelial injury, mucus plugging, and progressive airway remodeling 4, 5
- Type 2 inflammatory cascade involving IL-4, IL-13, and epithelial alarmins that amplify eosinophilic recruitment 4
Clinical Characteristics
Eosinophilic asthma typically manifests as:
- Adult-onset disease (intrinsic asthma), fundamentally different from childhood allergic asthma 1
- Persistently elevated blood eosinophil counts (not just variable elevations dependent on allergen exposure) 1
- Frequent severe exacerbations requiring systemic corticosteroids 6
- Association with chronic rhinosinusitis with nasal polyps in approximately 50% of cases 6
- Progressive airway obstruction that may become persistent and partially irreversible 7
Critical Distinction from Allergic Asthma
A pivotal concept: In allergen-driven childhood/adolescent asthma, eosinophils play only a minor "sidekick" role with variable counts dependent on allergen exposure. In contrast, eosinophils are persistently elevated and are crucial disease drivers in adult-onset eosinophilic asthma 1. This distinction has major implications for diagnosis and treatment selection.
Diagnostic Approach
Blood eosinophil count (BEC) remains the most accessible biomarker in clinical practice 4, but interpretation requires contextualization:
- Consider corticosteroid exposure (suppresses eosinophil counts)
- Account for biological variability over time
- Evaluate age at asthma onset
- Assess for comorbidities (chronic rhinosinusitis, nasal polyps)
- Recognize that no single biomarker fully reflects airway eosinophilia 4
A multidimensional assessment integrating clinical phenotype, longitudinal biomarkers, imaging, lung function, and therapeutic response is essential 4 rather than relying on BEC alone.
Therapeutic Implications
The recognition of eosinophilic asthma as a distinct entity has transformed treatment through targeted biologic therapies:
- Anti-IL-5 agents (mepolizumab, reslizumab) that directly target IL-5 6
- Anti-IL-5 receptor agents (benralizumab) targeting the alpha-subunit of IL-5 receptor 6
- Indirect modulators including anti-IL-4 receptor alpha (dupilumab) and anti-TSLP antibodies 3
These biologics demonstrate greater efficacy at higher baseline eosinophil levels and have proven effective even in patients with persistent airway obstruction 7, a population often excluded from clinical trials.
Clinical Pitfalls
Eosinophilia should not be considered a universal "treatable trait" across all chronic airway diseases but rather a complement to accurate clinical phenotyping 1. The critical error is treating elevated eosinophils in allergic childhood asthma the same way as in adult-onset eosinophilic asthma—these represent fundamentally different disease mechanisms requiring different therapeutic approaches.
Patients with severe eosinophilic asthma and persistent airway obstruction represent an underrepresented but high-burden group that may be referred to as having "persistent eosinophilic airway obstruction" 7, requiring specific consideration for IL-5-targeted biologics despite their exclusion from many clinical trials.